Basit öğe kaydını göster

Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update

dc.contributor.authorKabasakal, Levent
dc.contributor.authorDemirci, Emre
dc.contributor.authorToklu, Turkay
dc.contributor.authorAraman, Ahmet
dc.contributor.authorOcak, Meltem
dc.contributor.authorŞahin, Onural Alper
dc.contributor.authorAlan-Selcuk, Nalan
dc.date.accessioned2021-03-06T21:26:28Z
dc.date.available2021-03-06T21:26:28Z
dc.date.issued2018
dc.identifier.citationDemirci E., Kabasakal L., Toklu T., Ocak M., Şahin O. A. , Alan-Selcuk N., Araman A., "Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update", NUCLEAR MEDICINE COMMUNICATIONS, cilt.39, ss.789-796, 2018
dc.identifier.issn0143-3636
dc.identifier.othervv_1032021
dc.identifier.otherav_feb3afb8-9b75-4ef1-8a83-c9e3029646aa
dc.identifier.urihttp://hdl.handle.net/20.500.12627/166554
dc.identifier.urihttps://doi.org/10.1097/mnm.0000000000000874
dc.description.abstractPurpose Upon diagnosis, distant metastases are encountered in 21-50% of neuroendocrine tumours (NETs). However, few systemic treatment options are available for the well-differentiated NETs in the metastatic stage. Lu-177-DOTATATE is one of the most effective treatments in this limited patient group. We retrospectively investigated its efficacy and effect on the survival in patients with both well-differentiated and grade III NETs who had high uptake in pretherapeutic Ga-68-DOTATATE PET/computed tomography scans.
dc.language.isoeng
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectNükleer Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectRADYOLOJİ, NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME
dc.titleLu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update
dc.typeMakale
dc.relation.journalNUCLEAR MEDICINE COMMUNICATIONS
dc.contributor.departmentİstanbul Teknik Üniversitesi , Denizcilik , Deniz Ulaştırma İşletme Mühendisliği
dc.identifier.volume39
dc.identifier.issue8
dc.identifier.startpage789
dc.identifier.endpage796
dc.contributor.firstauthorID82088


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster